Biomolecules & Therapeutics

The Korean Society of Applied Pharmacology (한국응용약물학회)
권호 표지
DOI QR코드

DOI QR Code

Evaluation of Scopolamine Patch Pharmacotherapy for Motion Sickness in S. Korean

  • Lim, Sung-Cil (College of Pharmacy, CBITRC, Chungbuk National University) ;
  • Lee, Myung-Koo (College of Pharmacy, CBITRC, Chungbuk National University) ;
  • Lee, Chong-Kil (College of Pharmacy, CBITRC, Chungbuk National University) ;
  • Lee, Bo-Reum (College of Pharmacy, CBITRC, Chungbuk National University)
  • Published : 2008.06.30
Download PDF
⟨ Previous Next ⟩

Abstract

Scopolamine patch is an effective anticholinergic and antiemetic agent for motion sickness in S. Korea. Since this medication is Over The Counter (OTC) medication and may cause serious side effects when misused. Therefore, we evaluate the safety and efficacy for scopolamine patch in this study. We selected and surveyed total 43 patients who purchased scopolamine patch from three different pharmacies located at S and C Express Bus terminals and P Port at Seoul, Cheongju, and Busan. In the result, 11 patients (8${\sim}$15 year old:25.6%) were correctly used scopolamine patch with a children dose and 2 patients were misused. 26 (15${\sim}$60 year old: 60.4%) and 4 (over 6o year old: 9.3%) patients were correctly used with a adult dose. 33 patients (69.9%)answered that they knew the directions well how to use scopolamine patch correctly. Only 24.2% (n=8) patients learned the directions by pharmacist's consultation. Most patients (45 frequencies with duplicate counts) had some experienced side effects and among those drowsiness is the most common one. In conclusion, scopolamine patch as a non-prescription drug (OTC) should be monitored by pharmacist with correct drug consultation.

Keywords

References

  1. Attias, J., Gordon, C., Ribak, J., Binah, O., and Rolnick, A. (1987). Efficacy of transdermal scopolamine against seasickness: A 3-day study at sea. Aviat Space Environ Med. 58, 60-62
  2. Gonen, A., Gordon, C. R., Spitzer, O., Shahal, B., and Shupak, A. (1998). Comparison of performance under the influence of three anti-motion sickness drug. Aviat Apace Environ Med. 69, 209
  3. Gilman, A. G. et al. (ed.) (1990). The Pharmacological Basis of Therapeutics (8th Ed.); Pergamon Press, New York, NY. 150- 165
  4. Gorden, C., Binah, O., Attias, J., and Rolnick, A. (1986). Transdermal scopolamine: Human performance and side effects. Aviat Apace Environ Med. 57, 236-240
  5. Graybiel, A., Knepton, J., and Shaw, J. (1976). Prevention of experimental motion sickness by scopolamine absorbed through the skin. Aviat Apace Environ Med. 47, 1096-1100
  6. Hornby, P. J. (2001) Central neurocircuitry associated with emesis. Am J Med. 111, 106-12 https://doi.org/10.1016/S0002-9343(01)00849-X
  7. McEvoy, G. K. (8ed.) (1990). AHSF Drug Information; American Society of Hospital Pharmacists, Bethesda, MD. 608-611
  8. Nachum, Z., Shupak, A., and Gordon, C. R. (2006). Transdermal scopolamine for prevention of motion sickness. Clinical pharmacokinetics and Therapeutic Applications. 45(6), 543-66
  9. Parrott, A. C. (1989). Transdermal scopolamine: A review of its effects upon motion sickness, Psychological performance, and physiological functioning. Aviat Apace Environ Med. 60, 1-9
  10. Price, N. M., Schmitt, L. G., McGuire, J., Shaw, J. E., and Trobough, G. (1981). Transdermal scopolamine in the prevention of motion sickness at sea. Clin Pharmacol Ther. 29, 414-419 https://doi.org/10.1038/clpt.1981.57
  11. Shupak, A., Gordon, C. R., Spitzer, O., Mendelowitz, N., and Melamed, Y. (1989). Three years' experience of transdermal scopolamine: Long-term effectiveness and side-effects. Pharmatherapeutica. 5, 365-370